Amgen Inc. (NASDAQ:AMGN) Shares Sold by Leibman Financial Services Inc.

Leibman Financial Services Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,982 shares of the medical research company’s stock after selling 548 shares during the quarter. Amgen makes up about 2.7% of Leibman Financial Services Inc.’s portfolio, making the stock its 16th biggest holding. Leibman Financial Services Inc.’s holdings in Amgen were worth $3,861,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Strategic Financial Concepts LLC acquired a new position in Amgen in the 2nd quarter worth about $26,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen in the second quarter valued at approximately $30,000. nVerses Capital LLC acquired a new position in shares of Amgen during the 2nd quarter worth approximately $31,000. Bbjs Financial Advisors LLC purchased a new position in shares of Amgen during the 2nd quarter valued at approximately $33,000. Finally, FSA Wealth Management LLC grew its stake in Amgen by 182.0% in the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 0.1 %

AMGN opened at $317.68 on Wednesday. The stock has a market capitalization of $170.41 billion, a PE ratio of 45.38, a P/E/G ratio of 2.98 and a beta of 0.61. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The business’s 50 day moving average price is $326.97 and its 200 day moving average price is $309.76.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same period last year, the company earned $5.00 EPS. As a group, equities research analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is presently 128.57%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AMGN. TD Cowen upped their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a report on Thursday, September 26th. Dbs Bank raised Amgen to a “strong-buy” rating in a report on Monday, September 16th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $380.00 target price (up previously from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $326.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.